Cyclacel Pharmaceuti (CYCCP) 7.62 $CYCCP Cyclac
Post# of 273258
Posted On: 09/03/2016 1:24:42 AM
Cyclacel Pharmaceuti (CYCCP) 7.62 $CYCCP
Cyclacel Pharmaceuticals Reports 2nd Quarter 2016 Financial Results
GlobeNewswire - Wed Aug 10, 3:05PM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"
, a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today reported financial results and business highlights for the second quarter ended June 30, 2016.
CYCC: 5.71 (unch), CYCCP: 7.62 (-0.33)
Cyclacel Pharmaceuticals to Release Second Quarter 2016 Financial Results
GlobeNewswire - Wed Aug 03, 6:06AM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company", a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, will announce second quarter 2016 financial results on Wednesday, August 10, 2016. The Company will host a conference call and live webcast at 4:30 p.m. EDT on the same day.
CYCC: 5.71 (unch), CYCCP: 7.62 (-0.33)
Cyclacel's CYC065 Demonstrates Promising Activity in Uterine Serous Carcinoma in Preclinical Data Published by Independent Academic Researchers
GlobeNewswire - Tue Aug 02, 6:02AM CDT
- Data support CYC065 as potential treatment for chemotherapy-resistant, CCNE1-amplified,
CYCC: 5.71 (unch), CYCCP: 7.62 (-0.33)
Cyclacel Reports Updated Data From Its DNA Damage Response Program on Seliciclib and Sapacitabine Combination in Patients With Solid Tumors at ASCO
GlobeNewswire - Mon Jun 06, 9:00AM CDT
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), reported today updated Phase 1 data from its DNA damage response program evaluating a combination regimen of two Cyclacel product candidates, seliciclib, a cyclin dependent kinase (CDK) inhibitor, and sapacitabine, a nucleoside analogue. The regimen was orally-administered as sequential (Part 1) or concomitant (Part 2) treatment to 67 heavily-pretreated patients with advanced solid tumors. Antitumor activity was demonstrated in a subgroup of 45 patients with breast, ovarian and pancreatic cancers who tested positive for BRCA mutations (44 germline and 1 sporadic) with a 35.6% disease control rate (1 CR, 5 PR and 10 SD). Treatment durations in responders ranged between 16 and over 240 weeks. No CR or PR was observed in BRCA negative patients. Data were presented at an oral presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
CYCC: 5.71 (unch), CYCCP: 7.62 (-0.33)
Cyclacel Announces Reverse Stock Split
GlobeNewswire - Fri May 27, 4:00PM CDT
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company", a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that effective at 5:00 p.m., Eastern Time, on May 27, 2016 (the "Effective Time", the Company will effect a one-for-twelve reverse stock split of its outstanding common stock. The reverse stock split, which was unanimously approved by the Company's Board of Directors, was approved by its stockholders at the Annual Meeting of Stockholders held on May 26, 2016. The Company's common stock will open for trading on The NASDAQ Capital Market on May 31, 2016 on a post-split basis.
CYCC: 5.71 (unch), CYCCP: 7.62 (-0.33)
Cyclacel's Seliciclib-Sapacitabine Abstract Selected for Oral Presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire - Thu May 19, 6:00AM CDT
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), today announced the publication of an abstract selected for an oral presentation on Phase 1 data of an orally administered, combination regimen of seliciclib and sapacitabine in 67 patients with advanced solid tumors at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
CYCC: 5.71 (unch), CYCCP: 7.62 (-0.33)
Cyclacel Pharmaceuticals Reports First Quarter 2016 Financial Results
GlobeNewswire - Wed May 11, 3:05PM CDT
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company", a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today reported its financial results and business highlights for the first quarter ended March 31, 2016.
CYCC: 5.71 (unch), CYCCP: 7.62 (-0.33)
Cyclacel Pharmaceuticals to Release First Quarter 2016 Financial Results
GlobeNewswire - Wed May 04, 6:00AM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company", a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, will announce first quarter 2016 financial results on Wednesday, May 11, 2016. The Company will host a conference call and live webcast at 4:30 p.m. EDT on the same day.
CYCC: 5.71 (unch), CYCCP: 7.62 (-0.33)
Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, is an Effective Inducer of Cell Death in B-cell Lymphoma and Synergizes With Bcl-2 or BET Inhibitors
GlobeNewswire - Mon Apr 18, 8:00AM CDT
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), today announced the presentation of preclinical data demonstrating therapeutic potential of CYC065, the Company's second-generation, cyclin-dependent kinase (CDK) 2/9 inhibitor, as a targeted anti-cancer agent. The data show that CYC065 can induce cell death and combined beneficially with anti-cancer drugs from the Bcl-2 and BET inhibitor classes, in in vitro models of B-cell lymphoma, including double-hit lymphomas. The data were presented at the American Association for Cancer Research (AACR) Annual Meeting 2016, April 16 - 20, 2016, in New Orleans.
CYCC: 5.71 (unch), CYCCP: 7.62 (-0.33)
Cyclacel Announces Receipt of Nasdaq Extension
GlobeNewswire - Mon Apr 11, 6:00AM CDT
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC), (NASDAQ:CYCCP); ("Cyclacel" or the "Company" a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that the Company received a written ruling from the NASDAQ Hearings Panel (the "Panel" stating that the Panel has granted the Company's request to remain listed on The NASDAQ Capital Market.
CYCC: 5.71 (unch), CYCCP: 7.62 (-0.33)
Cyclacel Announces Receipt of Nasdaq Staff Determination; Company to Request Hearing
GlobeNewswire - Fri Feb 05, 3:20PM CST
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company" today announced that on February 2, 2016, the Company received a letter from the Listing Qualifications Staff (the "Staff" of The NASDAQ Stock Market LLC ("NASDAQ" indicating that the Company had not regained compliance with the $1.00 minimum bid price requirement for continued listing on The NASDAQ Capital Market, as set forth in NASDAQ Listing Rule 5450(a)(1), by the end of the previously granted compliance period that expired on February 2, 2016. As a result, the Staff indicated that the Company would be subject to delisting unless it timely requests a hearing before a NASDAQ Listing Qualifications Panel (the "Panel".
CYCC: 5.71 (unch), CYCCP: 7.62 (-0.33)
Cyclacel Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference
GlobeNewswire - Tue Feb 02, 6:00AM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that the Company will present at the 18 Annual BIO CEO & Investor Conference on February 8 at 10:30 a.m. EST at the Waldorf Astoria in New York City. Spiro Rombotis, President and Chief Executive Officer, will provide an overview of the Company and its progress in key programs.
CYCC: 5.71 (unch), CYCCP: 7.62 (-0.33)
BUYINS.NET: DSX, FFIC, PBS, XHB, CYCCP, DK Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Mon Jan 25, 6:34AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Diana Shipping Inc (NYSE
SX), Flushing Financial Corp (NASDAQ:FFIC), Powershares Dynamic Media Portfolio (NYSE
BS), Spdr S&P Homebuilders Etf (NYSE:XHB), Cyclacel Pharmaceuticals Inc (NASDAQ:CYCCP), Delek US Holdings Inc (NYSEK) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
PBS: 25.46 (+0.28), DSX: 2.32 (+0.05), CYCC: 5.71 (unch), XHB: 36.14 (+0.12), CYCCP: 7.62 (-0.33), FFIC: 23.20 (+0.05), DK: 17.52 (+0.21)
Molecular Basis for Development of Cyclacel's CYC065 CDK2/9 Inhibitor in Triple-Negative Breast Cancer Presented at San Antonio Breast Cancer Symposium
GlobeNewswire - Mon Dec 14, 6:00AM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company", today announced the presentation of preclinical data demonstrating the molecular basis for the development of CYC065 in triple negative breast cancer (TNBC), and in particular basal-like TNBC. CYC065 is a highly-selective, second-generation cyclin dependent kinase (CDK) inhibitor targeting CDK2/9 dependent tumors. The data were presented at the San Antonio Breast Cancer Symposium (SABCS), taking place December 8-12, 2015.
CYCC: 5.71 (unch), CYCCP: 7.62 (-0.33)
Cyclacel Pharmaceuticals Reports Third Quarter 2015 Financial Results
GlobeNewswire - Thu Nov 12, 3:11PM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company", a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today reported its financial results and business highlights for the third quarter ended September 30, 2015.
CYCC: 5.71 (unch), CYCCP: 7.62 (-0.33)
Mechanistic Rationale for CYC065, Cyclacel's CDK2/9 Inhibitor, in Targeted Solid Tumors and Hematological Malignancies Presented at AACR-NCI-EORTC International Conference
GlobeNewswire - Mon Nov 09, 6:00AM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company", today announced the presentation of preclinical data demonstrating the mechanistic rationale for the development of CYC065 in targeted solid tumors and leukemias. CYC065 is a highly-selective, second-generation cyclin dependent kinase (CDK) inhibitor targeting CDK2- and CDK9-dependent tumors. The data were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place November 5-9, 2015, in Boston.
CYCC: 5.71 (unch), CYCCP: 7.62 (-0.33)
Cyclacel Pharmaceuticals to Release Third Quarter 2015 Financial Results
GlobeNewswire - Thu Nov 05, 6:00AM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company", a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, will announce third quarter 2015 financial results on Thursday, November 12, 2015. The Company will host a conference call and live webcast at 4:30 pm Eastern time on the same day.
CYCC: 5.71 (unch), CYCCP: 7.62 (-0.33)
Data to be Presented on CYC065, Cyclacel's CDK2/9 Inhibitor, at AACR-NCI-EORTC International Conference
GlobeNewswire - Mon Oct 26, 3:05PM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company", today announced an upcoming presentation of preclinical data from a study with the Company's second generation cyclin dependent kinase (CDK) 2/9 inhibitor, CYC065, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, November 5-9, 2015, in Boston.
CYCC: 5.71 (unch), CYCCP: 7.62 (-0.33)
Cyclacel Doses First Patient in Phase 1 Trial of Its Novel CDK2/9 Inhibitor, CYC065, for the Treatment of Advanced Solid Tumors
GlobeNewswire - Thu Oct 22, 6:00AM CDT
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders today announced the dosing of the first patient in a Phase 1 trial of CYC065, the Company's novel second generation CDK (cyclin-dependent kinase) 2/9 inhibitor, for the treatment of advanced solid tumors. CYC065 was selected from the Company's discovery program in Dundee, Scotland and its development was supported in part by a UK government grant. In preclinical studies CYC065 has demonstrated anti-tumor activity as a single agent in hematological malignancies and solid tumors, including drug-resistant models. CYC065 also combined effectively with other targeted anticancer agents in drug-resistant solid tumor in vivo models. The objective of the Phase 1 trial is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of CYC065 in advanced cancer patients. The trial is being conducted at the Dana Farber Cancer Institute in Boston.
CYCC: 5.71 (unch), CYCCP: 7.62 (-0.33)
Cyclacel Presents Molecular Rationale for Clinical Development of CYC065 CDK Inhibitor in Leukemias and Lymphomas
GlobeNewswire - Thu Sep 17, 6:00AM CDT
-Preclinical data presented at the SOHO 2015 meeting-
CYCC: 5.71 (unch), CYCCP: 7.62 (-0.33)
Cyclacel Pharmaceuticals Reports 2nd Quarter 2016 Financial Results
GlobeNewswire - Wed Aug 10, 3:05PM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"
, a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today reported financial results and business highlights for the second quarter ended June 30, 2016. CYCC: 5.71 (unch), CYCCP: 7.62 (-0.33)
Cyclacel Pharmaceuticals to Release Second Quarter 2016 Financial Results
GlobeNewswire - Wed Aug 03, 6:06AM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"
, a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, will announce second quarter 2016 financial results on Wednesday, August 10, 2016. The Company will host a conference call and live webcast at 4:30 p.m. EDT on the same day. CYCC: 5.71 (unch), CYCCP: 7.62 (-0.33)
Cyclacel's CYC065 Demonstrates Promising Activity in Uterine Serous Carcinoma in Preclinical Data Published by Independent Academic Researchers
GlobeNewswire - Tue Aug 02, 6:02AM CDT
- Data support CYC065 as potential treatment for chemotherapy-resistant, CCNE1-amplified,
CYCC: 5.71 (unch), CYCCP: 7.62 (-0.33)
Cyclacel Reports Updated Data From Its DNA Damage Response Program on Seliciclib and Sapacitabine Combination in Patients With Solid Tumors at ASCO
GlobeNewswire - Mon Jun 06, 9:00AM CDT
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), reported today updated Phase 1 data from its DNA damage response program evaluating a combination regimen of two Cyclacel product candidates, seliciclib, a cyclin dependent kinase (CDK) inhibitor, and sapacitabine, a nucleoside analogue. The regimen was orally-administered as sequential (Part 1) or concomitant (Part 2) treatment to 67 heavily-pretreated patients with advanced solid tumors. Antitumor activity was demonstrated in a subgroup of 45 patients with breast, ovarian and pancreatic cancers who tested positive for BRCA mutations (44 germline and 1 sporadic) with a 35.6% disease control rate (1 CR, 5 PR and 10 SD). Treatment durations in responders ranged between 16 and over 240 weeks. No CR or PR was observed in BRCA negative patients. Data were presented at an oral presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
CYCC: 5.71 (unch), CYCCP: 7.62 (-0.33)
Cyclacel Announces Reverse Stock Split
GlobeNewswire - Fri May 27, 4:00PM CDT
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"
, a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that effective at 5:00 p.m., Eastern Time, on May 27, 2016 (the "Effective Time", the Company will effect a one-for-twelve reverse stock split of its outstanding common stock. The reverse stock split, which was unanimously approved by the Company's Board of Directors, was approved by its stockholders at the Annual Meeting of Stockholders held on May 26, 2016. The Company's common stock will open for trading on The NASDAQ Capital Market on May 31, 2016 on a post-split basis. CYCC: 5.71 (unch), CYCCP: 7.62 (-0.33)
Cyclacel's Seliciclib-Sapacitabine Abstract Selected for Oral Presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire - Thu May 19, 6:00AM CDT
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), today announced the publication of an abstract selected for an oral presentation on Phase 1 data of an orally administered, combination regimen of seliciclib and sapacitabine in 67 patients with advanced solid tumors at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
CYCC: 5.71 (unch), CYCCP: 7.62 (-0.33)
Cyclacel Pharmaceuticals Reports First Quarter 2016 Financial Results
GlobeNewswire - Wed May 11, 3:05PM CDT
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"
, a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today reported its financial results and business highlights for the first quarter ended March 31, 2016. CYCC: 5.71 (unch), CYCCP: 7.62 (-0.33)
Cyclacel Pharmaceuticals to Release First Quarter 2016 Financial Results
GlobeNewswire - Wed May 04, 6:00AM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"
, a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, will announce first quarter 2016 financial results on Wednesday, May 11, 2016. The Company will host a conference call and live webcast at 4:30 p.m. EDT on the same day. CYCC: 5.71 (unch), CYCCP: 7.62 (-0.33)
Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, is an Effective Inducer of Cell Death in B-cell Lymphoma and Synergizes With Bcl-2 or BET Inhibitors
GlobeNewswire - Mon Apr 18, 8:00AM CDT
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), today announced the presentation of preclinical data demonstrating therapeutic potential of CYC065, the Company's second-generation, cyclin-dependent kinase (CDK) 2/9 inhibitor, as a targeted anti-cancer agent. The data show that CYC065 can induce cell death and combined beneficially with anti-cancer drugs from the Bcl-2 and BET inhibitor classes, in in vitro models of B-cell lymphoma, including double-hit lymphomas. The data were presented at the American Association for Cancer Research (AACR) Annual Meeting 2016, April 16 - 20, 2016, in New Orleans.
CYCC: 5.71 (unch), CYCCP: 7.62 (-0.33)
Cyclacel Announces Receipt of Nasdaq Extension
GlobeNewswire - Mon Apr 11, 6:00AM CDT
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC), (NASDAQ:CYCCP); ("Cyclacel" or the "Company"
a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that the Company received a written ruling from the NASDAQ Hearings Panel (the "Panel" stating that the Panel has granted the Company's request to remain listed on The NASDAQ Capital Market. CYCC: 5.71 (unch), CYCCP: 7.62 (-0.33)
Cyclacel Announces Receipt of Nasdaq Staff Determination; Company to Request Hearing
GlobeNewswire - Fri Feb 05, 3:20PM CST
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"
today announced that on February 2, 2016, the Company received a letter from the Listing Qualifications Staff (the "Staff" of The NASDAQ Stock Market LLC ("NASDAQ" indicating that the Company had not regained compliance with the $1.00 minimum bid price requirement for continued listing on The NASDAQ Capital Market, as set forth in NASDAQ Listing Rule 5450(a)(1), by the end of the previously granted compliance period that expired on February 2, 2016. As a result, the Staff indicated that the Company would be subject to delisting unless it timely requests a hearing before a NASDAQ Listing Qualifications Panel (the "Panel". CYCC: 5.71 (unch), CYCCP: 7.62 (-0.33)
Cyclacel Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference
GlobeNewswire - Tue Feb 02, 6:00AM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that the Company will present at the 18 Annual BIO CEO & Investor Conference on February 8 at 10:30 a.m. EST at the Waldorf Astoria in New York City. Spiro Rombotis, President and Chief Executive Officer, will provide an overview of the Company and its progress in key programs.
CYCC: 5.71 (unch), CYCCP: 7.62 (-0.33)
BUYINS.NET: DSX, FFIC, PBS, XHB, CYCCP, DK Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Mon Jan 25, 6:34AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Diana Shipping Inc (NYSE
SX), Flushing Financial Corp (NASDAQ:FFIC), Powershares Dynamic Media Portfolio (NYSEBS), Spdr S&P Homebuilders Etf (NYSE:XHB), Cyclacel Pharmaceuticals Inc (NASDAQ:CYCCP), Delek US Holdings Inc (NYSEK) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: PBS: 25.46 (+0.28), DSX: 2.32 (+0.05), CYCC: 5.71 (unch), XHB: 36.14 (+0.12), CYCCP: 7.62 (-0.33), FFIC: 23.20 (+0.05), DK: 17.52 (+0.21)
Molecular Basis for Development of Cyclacel's CYC065 CDK2/9 Inhibitor in Triple-Negative Breast Cancer Presented at San Antonio Breast Cancer Symposium
GlobeNewswire - Mon Dec 14, 6:00AM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"
, today announced the presentation of preclinical data demonstrating the molecular basis for the development of CYC065 in triple negative breast cancer (TNBC), and in particular basal-like TNBC. CYC065 is a highly-selective, second-generation cyclin dependent kinase (CDK) inhibitor targeting CDK2/9 dependent tumors. The data were presented at the San Antonio Breast Cancer Symposium (SABCS), taking place December 8-12, 2015. CYCC: 5.71 (unch), CYCCP: 7.62 (-0.33)
Cyclacel Pharmaceuticals Reports Third Quarter 2015 Financial Results
GlobeNewswire - Thu Nov 12, 3:11PM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"
, a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today reported its financial results and business highlights for the third quarter ended September 30, 2015. CYCC: 5.71 (unch), CYCCP: 7.62 (-0.33)
Mechanistic Rationale for CYC065, Cyclacel's CDK2/9 Inhibitor, in Targeted Solid Tumors and Hematological Malignancies Presented at AACR-NCI-EORTC International Conference
GlobeNewswire - Mon Nov 09, 6:00AM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"
, today announced the presentation of preclinical data demonstrating the mechanistic rationale for the development of CYC065 in targeted solid tumors and leukemias. CYC065 is a highly-selective, second-generation cyclin dependent kinase (CDK) inhibitor targeting CDK2- and CDK9-dependent tumors. The data were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place November 5-9, 2015, in Boston. CYCC: 5.71 (unch), CYCCP: 7.62 (-0.33)
Cyclacel Pharmaceuticals to Release Third Quarter 2015 Financial Results
GlobeNewswire - Thu Nov 05, 6:00AM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"
, a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, will announce third quarter 2015 financial results on Thursday, November 12, 2015. The Company will host a conference call and live webcast at 4:30 pm Eastern time on the same day. CYCC: 5.71 (unch), CYCCP: 7.62 (-0.33)
Data to be Presented on CYC065, Cyclacel's CDK2/9 Inhibitor, at AACR-NCI-EORTC International Conference
GlobeNewswire - Mon Oct 26, 3:05PM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"
, today announced an upcoming presentation of preclinical data from a study with the Company's second generation cyclin dependent kinase (CDK) 2/9 inhibitor, CYC065, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, November 5-9, 2015, in Boston. CYCC: 5.71 (unch), CYCCP: 7.62 (-0.33)
Cyclacel Doses First Patient in Phase 1 Trial of Its Novel CDK2/9 Inhibitor, CYC065, for the Treatment of Advanced Solid Tumors
GlobeNewswire - Thu Oct 22, 6:00AM CDT
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders today announced the dosing of the first patient in a Phase 1 trial of CYC065, the Company's novel second generation CDK (cyclin-dependent kinase) 2/9 inhibitor, for the treatment of advanced solid tumors. CYC065 was selected from the Company's discovery program in Dundee, Scotland and its development was supported in part by a UK government grant. In preclinical studies CYC065 has demonstrated anti-tumor activity as a single agent in hematological malignancies and solid tumors, including drug-resistant models. CYC065 also combined effectively with other targeted anticancer agents in drug-resistant solid tumor in vivo models. The objective of the Phase 1 trial is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of CYC065 in advanced cancer patients. The trial is being conducted at the Dana Farber Cancer Institute in Boston.
CYCC: 5.71 (unch), CYCCP: 7.62 (-0.33)
Cyclacel Presents Molecular Rationale for Clinical Development of CYC065 CDK Inhibitor in Leukemias and Lymphomas
GlobeNewswire - Thu Sep 17, 6:00AM CDT
-Preclinical data presented at the SOHO 2015 meeting-
CYCC: 5.71 (unch), CYCCP: 7.62 (-0.33)
(0)
(0)Scroll down for more posts ▼